Active Biotech AB (publ) (LON: 0GQU)
London
· Delayed Price · Currency is GBP · Price in SEK 0.114
0.00 (0.00%)
At close: Jan 21, 2025
Active Biotech AB Company Description
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden.
It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that has completed phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors.
The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Active Biotech AB (publ)
| Country | Sweden |
| Founded | 1983 |
| Industry | Pharmaceutical Preparations |
| Employees | 8 |
| CEO | Helen Tuvesson |
Contact Details
Address: ScheelevAegen 22 Lund, 223 63 Sweden | |
| Phone | 46 46 19 20 00 |
| Website | activebiotech.com |
Stock Details
| Ticker Symbol | 0GQU |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Helen Tuvesson Ph.D. | President and Chief Executive Officer |
| Hans Kolam | Chief Financial Officer |
| Helena Eriksson | Chief Scientific Officer |